|
Friday, June 2, 2023, Chicago, Illinois, 11:45 AM – 12:45 PM Central Time (12:45 PM – 1:45 PM Eastern Time)
Lunch with the Investigators: Gastroesophageal CancersA CME Hybrid Symposium Held in Conjunction with the 2023 ASCO Annual Meeting
Location
Hilton Chicago 720 South Michigan Avenue Chicago, IL 60605 Phone: (312) 922-4400 Program Schedule — Central Time 11:30 AM – 11:45 AM — Registration and Lunch 11:45 AM – 12:45 PM — Educational Meeting Meeting Room Grand Ballroom (Level 2) This event will also be webcast live. Please see Registration tab for details. Faculty
Yelena Y Janjigian, MD Chief of Gastrointestinal Oncology Service Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Manish A Shah, MD Chief, Solid Tumor Oncology Service Director, Gastrointestinal Oncology Program Co-Director, Center for Advanced Digestive Care Bartlett Family Professor of Gastrointestinal Oncology Weill Cornell Medicine/NewYork-Presbyterian Hospital New York, New York Harry H Yoon, MD, MHS Professor of Oncology Enterprise-Wide Vice-Chair Gastrointestinal Cancer Disease Group Mayo Clinic Comprehensive Cancer Center Rochester, Minnesota Moderator Neil Love, MD Research To Practice Miami, Florida This activity is supported by educational grants from Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals Inc, Lilly, and Novartis.
Program Schedule — Central Time 11:30 AM – 11:45 AM — Registration and Lunch Buffet 11:45 AM – 12:45 PM — Educational Meeting MODULE 1: Integration of Immune Checkpoint Inhibitors into the Management of HER2-Negative Gastroesophageal (GE) Cancers
MODULE 2: Optimal Management of HER2-Positive GE Cancers
MODULE 3: Therapeutic Options for Relapsed/Refractory GE Cancers; Novel Investigational Approaches
Target Audience
CME Credit Form FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Janjigian — Advisory Committee and Consulting Agreements: AbbVie Inc, AmerisourceBergen, Arcus Biosciences, AskGene Pharma, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Geneos Therapeutics, GSK, Guardant Health, Imugene, Lilly, Lynx Health LLC, Merck, Merck Serono, Mersana Therapeutics Inc, Michael J Hennessy Associates Inc, Pfizer Inc, Rgenix, Seagen Inc, Silverback Therapeutics, Zymeworks Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Genentech, a member of the Roche Group, Lilly, Merck, Rgenix; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, Transcenta; Ownership – Private (Nonrelevant): Rgenix; Nonrelevant Financial Relationship: Clinical Care Options, Cycle for Survival, Fred’s Team, Imedex, National Cancer Institute, Paradigm Medical Communications, PeerView Institute, US Department of Defense. Dr Shah — Contracted Research: Bristol Myers Squibb, Merck, Oncolys BioPharma. Dr Yoon — Advisory Committee: ALX Oncology, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Elevation Oncology, MacroGenics Inc, Merck, Novartis, OncXerna Therapeutics, Zymeworks Inc; Consulting Agreements: Amgen Inc, Merck; Contracted Research: Amgen Inc, BeiGene Ltd, Bristol Myers Squibb, CARsgen Therapeutics, MacroGenics Inc, Merck; Travel: BeiGene Ltd.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals Inc, Lilly, and Novartis. Hilton Chicago
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastroesophageal cancers. IN-PERSON registration
Thank you for your interest in our CME program taking place in Chicago, IL. At this time online in-person preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 11:15 AM Central Time on Friday, June 2. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (720 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2023 ASCO Annual Meeting website. Please note: onsite registration does not guarantee meal service which will be based on availability.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. Registration for live webcast
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. Registration for Webcast »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation. |